Nucleolin Stabilizes Bcl-X<sub>L</sub> Messenger RNA in Response to UVA Irradiation

Jack Zhang,<sup>1</sup> George Tsaprailis,<sup>2</sup> and G. Tim Bowden<sup>1</sup>

<sup>1</sup>Azurio Cancer Center and <sup>2</sup>Center for Toxicology, University of Arizona, Tucson, Arizona

Abstract

Our laboratory has previously reported that UVA irradiation can increase the expression of Bcl-X<sub>L</sub>, an antiapoptotic molecule, by stabilizing its mRNA in cultured immortalized human keratinocytes. To understand the mechanism by which the Bcl-X<sub>L</sub> message is stabilized, we used a synthetic Bcl-X<sub>L</sub> 3′-untranslated region (UTR) to capture RNA-binding proteins. Nucleolin was identified as one of the binding proteins as determined by tandem mass spectrometry coupled to liquid chromatography analysis. Further study showed that nucleolin specifically recognized the AU-rich elements (AUUUA) in the 3′-UTR of the Bcl-X<sub>L</sub> mRNA and could stabilize the mRNA in vitro. Furthermore, overexpression of nucleolin stabilizes the Bcl-X<sub>L</sub> mRNA in HeLa cells, whereas reducing nucleolin by small interfering RNA shortens the Bcl-X<sub>L</sub> mRNA half-life. Interestingly, nucleolin physically interacted with polyadenylate [poly(A)]-binding protein through its RGG motifs. Its stabilizing effect on the Bcl-X<sub>L</sub> mRNA was dependent upon the presence of poly(A) tail. Based on these data, we propose a model in which nucleolin protects the Bcl-X<sub>L</sub> mRNA from nuclease degradation by enhancing the stability of the ribonucleoprotein loop structure.

Introduction

Skin cancer has become a serious health problem in the United States. Each year, there are more than one million new cases of skin cancer diagnosed, accounting for 40% of all cancer cases. Solid evidence has shown that UV irradiation from sunlight is the primary carcinogen for skin cancer (1–3). The UV irradiation can be categorized into UVA (320–400 nm), UVB (280–320 nm), and UVC (200–280 nm), based on its wavelength. UVA, composed of the vast majority of the irradiation from sunlight (90–99%), has been shown to be a potent skin carcinogen (3–5). For example, UVA promotes malignant transformation in cultured human keratinocytes (HaCaT cells; ref. 6) and causes malignant melanoma and squamous cell carcinoma in mouse models (7, 8). Specifically, UVA causes DNA damage by increasing reactive oxygen species and producing cyclobutane pyrimidine dimers (4, 9, 10). Additionally, UVA activates multiple signaling pathways, i.e., phosphoinositide 3-kinase, p38, and c-Jun-NH₂-kinase (JNK), important for cell survival upon UVA irradiation (6, 11, 12).

The antiapoptotic molecule Bcl-X<sub>L</sub> is crucial for the survival of many types of cells and has been implicated in differentiation and development (13, 14). For example, knockout of Bcl-X<sub>L</sub> is lethal in mice, resulting from extensive death of hematopoietic cells and atrophy of the brain (15). On the other hand, substantial induction of this molecule renders activated T cells resistant to apoptosis upon CD28 stimulation (16). Its importance can be further illustrated by its involvement in cancer development. Overexpression of Bcl-X<sub>L</sub> is observed in several types of cancers, i.e., colorectal and breast cancer (14, 17). The importance of Bcl-X<sub>L</sub> in skin carcinogenesis has been well defined in both cultured cells and animal models (18, 19). Furthermore, Bcl-X<sub>L</sub> confers drug resistance in multiple cancers (20, 21) and inversely correlates with prognosis in some cancers (22). Therefore, a thorough understanding of the regulation of Bcl-X<sub>L</sub> will pave the way for novel strategies of cancer chemotherapy and chemoprevention.

Bcl-X<sub>L</sub> primarily localizes to the mitochondrial membrane. Through its BH1-3 domains, Bcl-X<sub>L</sub> is able to bind and sequester proapoptotic molecules possessing the BH-3 domain (23). The primary targets for Bcl-X<sub>L</sub> are Bax and Bak, which migrate to and oligomerize on the outer mitochondrial membrane and thus change the permeability of the mitochondria, leading to the release of small molecules, including cytochrome c. The release of cytochrome c triggers the assembly of apoptosomes and, thus, activation of caspase cascade (13, 14, 17). It has been postulated that Bcl-X<sub>L</sub> blocks the oligomerization of Bax and Bak and, thus, the release cytochrome c (23).

The expression of Bcl-X<sub>L</sub> is tightly regulated at transcriptional (24, 25), alternatively splicing (24), and translational levels (16). Recently, our laboratory has shown that its mRNA stability can also be regulated in human keratinocytes upon irradiation with 250 kJ/m² UVA. Furthermore, this stabilization is dependent upon the 3′-UTR of the Bcl-X<sub>L</sub> mRNA (26). However, the mechanism for the mRNA stabilization of the Bcl-X<sub>L</sub> mRNA is unclear.

The regulation of mRNA stability enables cells to rapidly adjust to environmental changes (27, 28). Indeed, mRNAs of some regulatory molecules, such as c-myc, cyclins, p27, cyclooxygenase-2 (Cox-2), and interleukin 2 (IL-2), are normally short-lived, and their stability is subject to change upon external stimulation (29). In mammalian cells, the rate-limiting step of mRNA degradation is polyadenylate [poly(A)] deadenylation, which is mediated by PARN (28). Shortening of poly(A) tail to ~30 to 60 nucleotides in mammalian cells is required for mRNA degradation (30). After deadenylation, hydrolysis of 5′ m7G cap takes place, allowing degradation of decayed mRNA by 5′-3′ exoribonuclease, Xrn1 (31–33). However, it has been argued that the primary degradation pathway in mammalian cells is mediated by exosomes, complexes composed of at least ten 3′-5′ exonucleases (28, 31, 32).

It has been shown that stability of many mRNAs is dependent upon their 3′-UTRs, including those of cyclins, Cox-2, IL-2, renin, c-myc, IL-6, granulocyte macrophage colony-stimulating factor,
ferritin, and glucose transport 1 (27–29, 34). Prominently, a cis-element, AU-rich element (ARE), has been well defined and shown to be critical for the stability of these mRNAs. It was estimated that 5% to 8% of all mRNAs contain variable numbers of AREs (27, 34).

Despite the fact that ARE was identified >15 years ago, the mechanism of how it functions was not unraveled until recently. Several studies related to known ARE-binding proteins indicated that some ARE-binding proteins physically interact and thus recruit RNA decay machinery to accelerate RNA degradation. For example, K homology splicing regulatory protein (KSRP) has been known as a destabilizing factor. In a recent study, Chou et al. made a fusion protein between KSRP and MS2, a bacteriophage coat protein. This fusion protein led to a dramatic decrease in the β-globin message that contained six MS2 binding sites. Furthermore, they found that PARN and RRP4 exosome components could be communoprecipitated with KSRP (35). These data suggested that KSRP accelerates mRNA degradation by recruiting the PARN and exosomes. Similarly, other studies showed that two other destabilizing ARE-binding proteins, Tristetraprolin and ARE/poly(U)-binding/degradation factor 1 (AUF1), could also associate with exosomes (31).

Meanwhile, a number of studies also showed a stabilizing function of AREs (36–39). For example, HuR can stabilize a number of messages, such as β-casein, SLC11A1, p21, cyclins A and B1, Cox-2, and renin, through the ARE element (40). One ubiquitous protein, nucleolin, has also been reported to stabilize several messages, such as Bcl-2, IL-2, and Gadd45 (37, 38, 41).

To understand how the Bcl-XL mRNA was stabilized upon UVA irradiation in human keratinocytes (HaCaT cells), we identified nucleolin as one of the proteins binding to the 3′-UTR of the mRNA. In this report, we provide evidence that nucleolin can bind to the ARE element on the 3′-UTR of the Bcl-XL mRNA and stabilize the message in vitro and in vivo. Moreover, nucleolin stabilization of the Bcl-XL mRNA is dependent on the poly(A) tail and poly(A) binding protein (PABP). Finally, we offer a model to explain how nucleolin stabilizes the Bcl-XL mRNA.

Materials and Methods

Plasmids. Constructs expressing the wild-type and ARE-mutated Bcl-XL (NM_001191) 3′-UTR (1287nt) were cloned as followed. The UTRs were dropped out by Eagl from the UTR-luciferase reporter constructs (26) and then religated to NotI-digested pbBlueScript II K5 (−) plasmid (Stratagene). The construct was named pBS-1287UTR(WT). The full length Bcl-XL was cloned by reverse transcription–PCR (RT-PCR). Briefly, total RNA extracted from HaCaT cells (immortalized human keratinocytes) with Trizol (Invitrogen) were reverse-transcribed with ProtoScript II RT-PCR kit (New England Biolabs). The primers for the subsequent PCR amplification were 5′-ctctcagctggacggagccct-3′ and 5′-tggtctcaagagaatggctactagctgcaag-3′ (ARE1), 5′-ccccctaagagccacccagacttttcggtcgtg-3′ and 5′-agtttaagcgccccagtggctctaggg (ARE2), and 5′-tttgtagagcttgctaccagtgag-3′ and 5′-agagctctcactggctgtaacagccagcctttttgact-3′ (ARE3).

RNA affinity chromatography. UVA and SB202190 treatment of HaCaT cells (immortalized human keratinocytes) was described previously (26). These samples were subject to the RNA affinity chromatography as described by Cok et al. (45). Briefly, the treated cells were washed twice with cold PBS and scraped off the plate with the EMSA binding buffer [10 mmol/L HEPES (pH 7.6), 5 mmol/L MgCl2, 40 mmol/L KCl, 1 mmol/L DTT, 5% glycerol, 5 mg/mL heparin]. The cells were sonicated and centrifuged. The supernatant was used for the subsequent RNA binding assay. To transcribe Bcl-XL 3′-UTR in vitro, the construct pBS-1287UTR(WT) was completely digested by Xhol and phenol extracted. This linearized DNA template was transcribed and biotinylated with MEGAscript T7 kit (Ambion) according to the manufacturer’s instructions. Subsequently, 500 μg cell lysate were incubated with 20 μg of biotinated RNA on ice for 1 h. The mixture was further incubated with 0.2 mL Streptavidin Sepharose beads (Amersham) overnight at 4°C with rotation. The beads were loaded on a column and washed with 20 mL of the binding buffer. The beads were boiled with SDS-PAGE loading buffer to release captured proteins, which were resolved on a SDS-PAGE gel. The proteins were silver-stained with a mass spec compatible kit (Invitrogen) and those differentially captured bands were excised for mass spec analysis.

Tandem mass spectrometry coupled to liquid chromatography. Excised protein bands after SDS-PAGE were digested in trypsin (10 μg/mL) at 37°C overnight. Tandem mass spectrometry coupled to liquid chromatography (LC-MS/MS) analyses of in-gel trypsin digestion was performed as previously described (46). Protein bands were analyzed using a quadrupole ion trap ThermoFinnigan LCQ DECA Xp PLUS equipped with a Michrom Paradigm MS4 HPLC and a nanoelectrospray source. Peptides were eluted from a 15-cm pulled tip capillary column (100 μm ID, 360 μm O.D.; 3–5 μm tip opening) packed with 7 cm Vydoc C18 material (5 μm, 300 Å pore size), using a gradient of 0 to 65% solvent B (98% methanol:2% water:0.5% formic acid:0.01% trifluoroacetic acid) over a 60-min period at a flow rate of 350 nL/min. The LCQ DECA XP PLUS electrospray positive mode spray voltage was set at 1.6 kV, and the capillary temperature was at 200°C. Dependent data scanning was performed by the Xcalibur v 1.3 software (47) with a default charge of 2, an isolation width of 1.5 amu, an activation amplitude of 35%, an activation time of 30 ms, and a minimal signal of 10,000 ion counts. Global dependent data settings were as follows: reject mass width of 2, an isolation width of 1.5 amu, an activation amplitude of 35%, a dCn mass tolerance was set at 0.5 amu during the search. The criteria that were used for a preliminary positive peptide identification are the same as previously described, namely peptide precursor ions with a +1 charge having an Xcorr of >1.8, +2 Xcorr of >2.5, and +3 Xcorr of >3.5. A dCn score of >0.08 and a fragment ion ratio of experimental/theoretical of >50% were also used as filtering criteria for reliable matched peptide identification (49). All matched peptides were confirmed by visual examination of the spectra. All spectra were searched against the latest version of the nonredundant protein database downloaded on July 14, 2005 from National Center for Biotechnology Information (NCBI). At the time of the search, the nonredundant protein database from NCBI contained 2,662,317 entries.

UV-crosslinking assay. The Bcl-XL 3′-UTR was synthesized and 32P-labeled from Xhol linearized pBS-1287(WT) plasmid with the Riboprobe.
In vitro Transcription System (Promega). After removal of unincorporated nucleotides by P-6 minicolumn (Bio-Rad), 5 million counts per million were incubated with 0.1 μg of MBP-Nucleolin on ice for 30 min, followed by UV cross-linking by Geneinker (Bio-Rad). RNase A1 (2.5 μg; Sigma) was added to the reaction and incubated at 37°C for 1 h. The reaction was resolved on a SDS-PAGE gel and autoradiographed.

RNA immunoprecipitation and RT-PCR. RNA immunoprecipitation was performed as previously described (41). Briefly, HaCaT cells were lysed with radioimmunoprecipitation assay (RIPA) buffer with protease inhibitors. Antibodies (2 μg) were incubated with 500 μg lysates for 4 h at 4°C. Protein A/G beads (Santa Cruz Biotech) were added and incubated overnight at 4°C. The beads were washed five times with RIPA buffer, and RNA was extracted with Trizol reagent (Invitrogen). The extracted RNA was reverse-transcribed with the Protoscript First Strand cDNA synthesis kit (New England Biolabs) and followed by PCR to generate a Bcl-XL specific fragment with the primer set: cattgccaccaggagaaccactac (forward) and catcttatcttcccaagcagcct (reverse).

Cell transfection. The transfection of pEGFP-nucleolin (generous gift from Dr. Kastan) was performed with Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instructions. The transfection of the nucleolin and control small interfering RNA (siRNA; Qiagen) was performed according to the manufacturer’s instruction. The transfection of the catctttatcccaagcagcct (reverse).

Results

Nucleolin is identified as one of the proteins binding to the Bcl-XL 3'-UTR. Our laboratory has reported that in HaCaT cells, Bcl-XL mRNA is stabilized through its 3'-UTR upon UVA irradiation (26). Because 3'-UTRs confer mRNA stability by interacting with different RNA-binding proteins (27, 34, 50), we hypothesized that the Bcl-XL mRNA was stabilized by a similar mechanism. Specifically, there might be more stabilizing factor binding to the Bcl-XL 3'-UTR upon UVA irradiation in HaCaT cells. To test this idea, we started with identifying RNA-binding proteins that could be differentially captured from the mock-treated or UVA-treated HaCaT cells. Moreover, because this stabilization was dependent upon p38 mitogen-activated protein kinase (MAPK; ref. 26), we inhibited p38 MAPK with 5 μmol/L of SB202190 in the UVA-treated cells. We used a synthetic 1287nt wild-type Bcl-XL 3'-UTR to capture RNA-binding proteins from the above cell lysates. After the proteins were resolved by SDS-PAGE and silver-stained, we found that there were at least 10 protein bands that were differentially captured (Fig. 1, lanes 1 and 2). One of the captured proteins increased by UVA irradiation and inhibited by SB202190 was excised and identified with LC-MS/MS.

The encircled band in Fig. 1 was subsequently identified as nucleolin. Figure 2A showed the LC-MS/MS trace of the trypsin-digested SDS-PAGE protein band. A search of the MS/MS spectra (see Materials and Methods) identified seven peptides from nucleolin, mapping 14% of the primary protein sequence (Fig. 2B and C). The MS/MS spectra of these peptides showing the various fragment ions that were found are shown in Fig. 2D.

To validate the mass spectrometry results, we used Western blot analysis to detect the presence of nucleolin from the RNA affinity chromatography. As expected, we found that the specific anti-nucleolin antibody recognized nucleolin (Fig. 3A, top). Furthermore, we noticed that nucleolin captured from the UVA-treated sample was more abundant than that from the mock-treated sample (Fig. 3A, lane 3), given that the input nucleolin was equal (Fig. 3A, bottom). These data indicated that UVA treatment
enhanced the nucleolin binding to the 3’-UTR of the Bcl-X<sub>L</sub> mRNA and thus supported our initial hypothesis. This is consistent with the previous finding that UV increases the nucleolin binding to TAR (HIV-1 transactivation responsive region) RNA probe in RKO cells (51).

To rule out the possibility that RNA affinity chromatography might capture nonspecific proteins, we used the UV cross-linking assay to prove the specific binding of nucleolin to the 3’-UTR of Bcl-X<sub>L</sub>. The cross-linking between protein and RNA would form covalent bonds between protein and RNA and thus shield the

---

**Figure 2.** Mass spectrometry base peak chromatogram (LC-MS) of the in-gel digested SDS-PAGE band corresponding to nucleolin. A, a typical MS/MS spectrum for one of the peptides identified from nucleolin is also shown along with its corresponding b/y fragment ions used in determining the sequence (B). A total of seven high-scoring peptides (C) as described in Materials and Methods were identified covering 14% (bold) of the primary sequence of nucleolin (D).
protein-bound RNA region from subsequent nuclease A1 digestion (52). As shown in Fig. 3B, when there was no UV cross-linking, the RNA was completely degraded (Fig. 3B, lane 1). In contrast, after being cross-linked, a band appeared at 90 to 100 kDa, the predicted size of the recombinant nucleolin, indicating that the recombinant nucleolin binds to the 3′-UTR and therefore protected its binding region from nuclease digestion.

Nucleolin binds to AREs of the 3′-UTR. Next, we sought to investigate what cis-element on the 3′-UTR nucleolin bound. It has been reported that nucleolin binds to ARE of several other mRNA molecules, including Bcl-2 (37, 38). We found that there are three regions when all of the three AREs were mutated (Fig. 3C). We showed that nucleolin binds to the 3′-UTR nucleolin failed to protect any fragment at 4 h (without nucleolin) to ~4 h (with nucleolin). Therefore, nucleolin was able to stabilize the Bcl-XL mRNA in vitro (Fig. 4A).

To examine whether nucleolin can also stabilize the mRNA in living cells, we compared the half-lives of the Bcl-XL mRNA in HeLa cells with gain-of-function or loss-of-function of nucleolin. HeLa cells have similar responses to UV irradiation and are easier to transfect. In comparison, the transfection efficiency is very low in HaCaT cells. We transfected HeLa cells with pEGFP-nucleolin or the empty control vector pEGFP-C1. There was ~40% to 50% of the cells expressing green fluorescence 20 h after transfection (data not shown). We found that overexpression of Bcl-XL does extend the half-life of the Bcl-XL mRNA to longer than 6 h (Fig. 4B).

To support the above result, we also used siRNA to knockdown nucleolin expression. We found that there was a 60% reduction of nucleolin protein after 60 h of the siRNA treatment compared with the negative control (data not shown). Therefore, we compared the half-lives of the Bcl-XL mRNA in these cells. As shown in Fig. 4C, there was a reduction of the Bcl-XL mRNA in the nucleolin siRNA-treated cells.

In Fig. 3C, we showed that nucleolin binds to the 3′-UTR of the Bcl-XL mRNA. We reasoned that this binding is important for the nucleolin regulation of the Bcl-XL mRNA. To test this idea, we cotransfected the cells with nucleolin and luciferase reporter fused to the Bcl-XL 3′-UTR. We found that cotransfection with nucleolin increased the luciferase activity to ~9-fold compared with the empty vector (pEGFP-C1) control (Fig. 4D), indicating that the 3′-UTR may confer nucleolin stabilization of the Bcl-XL mRNA.

Poly(A) tail is required for the nucleolin stabilization of Bcl-XL. It has been an intriguing goal to understand how AREs and RNA-binding proteins modulate stability of their targets. There are two possibilities for nucleolin stabilization of Bcl-XL mRNA. One is that nucleolin binds to a certain region and protects that region from degradation. Alternatively, nucleolin may help protect the mRNA poly(A) tail from deadenylation, which is the first step for mRNA degradation. To distinguish the two possibilities, we devised a simple experiment. We synthesized the mRNA with or without the poly(A) tail and compared the nucleolin stabilization effects on these two RNA species. We reasoned that for the first possibility, nucleolin would have the same effect on the RNA
stability using both mRNA species. However, the half-lives of the two mRNA species were different, indicating that nucleolin failed to stabilize the mRNA without polyadenylation (Fig. 5A). These results supported the second possibility that nucleolin might help protect the poly(A) tail from deadenylation.

To rule out the possibility that the differential stabilization resulted from the poly(A) per se, the polyadenylated mRNA was incubated with S100 in the absence of nucleolin. As shown in Fig. 5A, this mRNA was degraded rapidly. Therefore, it was nucleolin, but not poly(A) tail, that stabilized RNA in this assay. In summary, this result also showed that the nucleolin stabilization effect was dependent upon poly(A) tail.

**Nucleolin has a physical interaction with PABP.** As the poly(A) tail is important for the nucleolin stabilization of Bcl-XL mRNA and the poly(A) tail is primarily bound by the PABP, we reasoned that this stabilization might be achieved through a physical interaction between nucleolin and PABP. To test this hypothesis, we used the purified recombinant proteins to examine their interactions. We reasoned that if they interacted with each other, pulling down either one of them could capture the other by affinity chromatography. Therefore, we used amylase resin to pull down MBP-tagged nucleolin and Ni-NTA agarose for His6-tagged PABP. As shown in Fig. 5B, nucleolin was detected in amylase resin (lanes 2 and 3) as expected. In Ni-NTA agarose, however, nucleolin was detected only when incubated with His6-PABP (Fig. 5C, lane 3). In comparison, nucleolin did not bind to the Ni-NTA beads (Fig. 5C, lane 2). Conversely, PABP did bind to Ni-NTA agarose (Fig. 5D, lanes 1 and 3) as expected, but it could only be detected in the amylase resin when incubated with MBP-nucleolin (Fig. 5E, lane 3). These results indicated that PABP and nucleolin interact with each other in vitro, and this interaction is not RNA dependent.

Nucleolin has four RNA-binding domains and nine Arg-Gly-Gly (RGG) motifs (43) at its COOH terminus. It has been shown that these RGG motifs are involved in interacting with both ribosomal proteins (55) and DNA G-quadruplex (43). Using the recombinant nucleolin with different domains, we found that the recombinant protein Nuc-RGG9 alone was able to pull down PABP (Fig. 5F, lane 2) even in the absence of any RNA-binding domains, whereas
the truncated region Nuc-RGG4 failed to do so (Fig. 5F, lane 1).

This result is similar to the previous report that the binding of Nuc-RGG9 to DNA G-quadruplex was abolished when Nuc-RGG9 was truncated to Nuc-RGG4 (43). Therefore, our data suggested that the full-length RGG motifs are required for interacting with PABP and the RNA binding domains may not be necessary for this interaction. Because the MBP fusion proteins were used in the experiments, we examined if MBP alone could interact with PABP. As shown in Fig. 5F (lane 3), there was no PABP detected. This result ruled out the possibility that MBP interacts with PABP.

To test if nucleolin interacts with PABP in intact cells, we used reciprocal immunoprecipitation to pellet both proteins. As expected, nucleolin was detected in the sample precipitated with the anti-PABP antibody (Fig. 6A), whereas the control IgG did not pellet nucleolin. Similarly, PABP was present in the antinucleolin antibody–precipitated sample (Fig. 6B). Therefore, these data strongly showed that PABP interacts with nucleolin.

**Discussion**

The antiapoptotic molecule Bcl-XL has been implicated in tumor initiation, malignancy, and drug resistance (17, 20, 21, 56). Its importance in skin carcinogenesis has also been illustrated in both cell cultures and mouse models (18, 19, 22). Therefore, a better understanding of its regulation may shed light on novel strategies for skin cancer prevention and treatment. In this study, we provide evidence that nucleolin can stabilize the Bcl-XL mRNA by binding to the ARE elements of the 3′-UTR in vitro. Furthermore, we show that this stabilization effect is dependent upon the presence of poly(A) tail. This mechanism is similar to the stabilization of Bcl-2 mRNA, suggesting that there might be a conserved regulatory mechanism between these two mRNAs (37).

To better understand the molecular mechanism whereby the Bcl-XL mRNA is stabilized upon UVA irradiation, we used RNA affinity chromatography to capture proteins that were differentially bound to the Bcl-XL 3′-UTR. This technique has been successfully used in identifying RNA-binding proteins, i.e., Renin (57), and nucleoplasmin (51). In our experiment, we found that at least 10 protein bands were differentially bound to the RNA column upon UVA irradiation. One of the bands was identified as nucleolin (Fig. 1). Nucleolin possesses four RNA-binding domains and reportedly stabilizes multiple RNA molecules (38, 41, 51). Interestingly, nucleolin stabilizes the Bcl-2 mRNA in HL-60 cells (37). Furthermore, we found that the binding of nucleolin to the beads increased in UVA-irradiated cells, indicating that nucleolin may play a role in...
the UVA response in human keratinocytes (Fig. 1, lane 2 and Fig. 3A, lane 3, top). Therefore, we reasoned that nucleolin might bind to and stabilize the Bcl-XL mRNA in UVA-irradiated human keratinocytes.

Nucleolin is a ubiquitously expressed protein and involved in important biological processes, such as cell cycle regulation and ribosomal biogenesis (58). Nucleolin has been implicated in apoptosis through various mechanisms. For example, overexpression of nucleolin increases the expression of p53 protein and thus promotes apoptosis in HCT116 or U2-OS cells by inhibiting MDM2-mediated ubiquitination (59). In contrast, nucleolin is antiapoptotic in other studies (37, 38, 51). Our data are consistent with previous findings that nucleolin regulates gene expression by stabilizing mRNAs (37, 38, 41). For example, nucleolin, together with another protein YB-1, stabilizes IL-2 mRNA in a JNK kinase-dependent manner (40). These two proteins recognize a cis-element called JNK response element at the 5'UTR of IL-2 and stabilize IL-2 mRNA both in vitro and in vivo.

How nucleolin stabilizes the Bcl-XL mRNA remains unclear. In this report, we provide evidence that nucleolin binding of Bcl-XL requires the poly(A) tail and that there is a physical interaction between nucleolin and PABP. Our data suggest that nucleolin-PABP interaction may also be direct, because the recombinant proteins interact with each other in the absence of any RNA (Fig. 5). Furthermore, our data suggest that all RGG motifs of nucleolin may be required for this interaction (Fig. 5E).

The biological significance of the PABP-nucleolin interaction is not clear. A similar finding was reported. HuR, a well-studied RNA-stabilizing protein, was found to interact with PABP. Nagao et al. reported that HuR-PABP interaction is essential to the β-casein mRNA stability (40). Likewise, we postulate that interactions between PABP and RNA-stabilizing proteins, i.e., nucleolin, may block the action of PARN and therefore slow down deadenylation process. Furthermore, PABP has been shown to interact with proteins binding to the 5'-UTR, i.e., eIF, forming a RNA loop structure that stabilizes mRNA and facilitates translation. Therefore, we propose a similar model contributing to UVA-mediated resistance to apoptosis in human keratinocytes. In this model, UVA irradiation increases the binding capacity of nucleolin to the AREs on the 3'-UTR of Bcl-XL mRNA in a p38 MAPK-dependent manner. Subsequently, nucleolin binds to PABP in proximity through the RGG motifs, and this interaction helps stabilize the mRNA loop structure by excluding access of PARN and exosomes from digesting the poly(A) tail. Consequently, the Bcl-XL mRNA is stabilized and its expression increased.

This model does not exclude the possibility that nucleolin may also displace other destabilizing factors from the 3'-UTR. RNA-binding proteins may compete with same cis-elements. For example, HuR binding to the iNOS mRNA is mutually exclusive with KSRP binding (36). Similarly, HuR has been considered to compete with AUFI (45). Finally, we have considered the possibility that p38-mediated phosphorylation of nucleolin prevents the recruitment of other destabilizing proteins, i.e., Tristetraprolin and KSRP to mRNAs (35).

In this study, we provide evidence showing that nucleolin binds to the ARE of the 3'-UTR of the Bcl-XL mRNA and stabilizes the message both in vitro and in vivo. Because of the importance of Bcl-XL in skin carcinogenesis, a better understanding of its regulation can be helpful for devising novel strategies for treatment and prevention of skin cancers.

Acknowledgments

Received 5/23/2007; revised 10/1/2007; accepted 12/19/2007.

Grant support: NIH grants CA20374, CA46584, and CA27502. Mass spectrometric data were acquired by the Arizona Proteomics Consortium supported by NIH grant ES06694 to SWEHSC, NIH/National Cancer Institute grant CA20374 to AZCC, and Bios Institute of the University of Arizona.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

We thank Drs. Kieldjian, Maizels, and Kastan for providing reagents and Anne Cione for her administrative assistance.

References

16. Bachelor MA, Bowden GT. Ultraviolet A-induced...


Nucleolin Stabilizes $Bcl-X_L$ Messenger RNA in Response to UVA Irradiation

Jack Zhang, George Tsaprailis and G. Tim Bowden


Updated version

Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/68/4/1046

Cited articles

This article cites 59 articles, 31 of which you can access for free at:
http://cancerres.aacrjournals.org/content/68/4/1046.full#ref-list-1

Citing articles

This article has been cited by 18 HighWire-hosted articles. Access the articles at:
http://cancerres.aacrjournals.org/content/68/4/1046.full#related-urls

E-mail alerts

Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions

To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions

To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.